Redeye has revised its estimates following Heliospectra’s Q3 2025 report. Despite softer sales in 2025, the company continues to advance its long-term growth agenda, reinforced by a strengthened leadership team, an expanding greenhouse project pipeline, and the establishment of a new reference site in North America. Ongoing innovation and a planned rights issue further position Heliospectra to secure larger projects and accelerate growth in 2026 and beyond.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/